文献速递肺结节与肺癌

美国肺结节当代评估与管理:混合方法研究

Contemporary Pulmonary Nodule Evaluation and Management in the United States A Mixed-Methods Study.
PubMed 文献 · Chest · 2026-07-28

多数医生使用风险评估工具(70.8%),认为肺结节评估具挑战性(71.4%),仅50.5%拥有提供最佳诊疗所需的临床资源。

要点

  • 70.8%的受访医生使用风险评估工具评估肺结节癌变风险,临床预测模型(70.3%)比商业生物标志物(18.8%)更常用。
  • 95.8%的医生认同肺结节评估需要共享决策,91.1%认同需要多学科协作,85.9%认为需要改进。
  • 仅50.5%的医生报告拥有提供最佳肺结节诊疗所需的临床资源,结节追踪与风险评估工具被列为改进优先事项。

核心结论

  • 临床医生认为肺结节评估具有挑战性,需要多学科协作、共享决策和改进,但许多人缺乏提供最佳诊疗所需的足够资源。
  • 未来工作应聚焦于改善系统层面的肺结节追踪和癌症风险评估。

研究设计与样本

  • 探索性序贯混合方法研究,先对40名多专科临床医生进行半结构化定性访谈,主题分析后开发并实施全国在线定量调查。

主要发现

  • 70.8%的临床医生报告使用风险评估工具评估肺结节癌症风险,临床风险预测模型(70.3%)比商业生物标志物(18.8%)更常用。
  • 63.5%的参与者认为理想的风险评估工具应优先避免漏诊肺癌,而非避免不必要的侵入性操作。
  • 71.4%的临床医生认为肺结节评估具有挑战性,95.8%认同需要共享决策,91.1%认同需要多学科协作,85.9%认为需要改进。
  • 仅50.5%的临床医生报告拥有提供最佳肺结节诊疗所需的临床资源。
  • 参与者将肺结节追踪和风险评估工具列为改善肺结节临床诊疗的最高优先事项。

临床怎么用

  • 临床实践中应重视使用临床风险预测模型评估肺结节癌症风险。
  • 肺结节管理应纳入共享决策和多学科协作流程。
  • 系统层面应优先建设肺结节追踪体系和风险评估工具,以弥补临床资源不足。

局限性

  • 调查回复率较低(192/3588,5.4%),可能存在无应答偏倚。
  • 研究为探索性混合方法设计,定量结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effective evaluation and management of pulmonary nodules (PNs) are essential to diagnosing early-stage lung cancers while avoiding unnecessary invasive procedures. There are key knowledge gaps in how clinicians manage PNs and which opportunities for improvement should be prioritized. RESEARCH QUESTION: Which factors contribute to clinicians' PN evaluation and management practices, and what are perceived barriers to optimal clinical care? STUDY DESIGN AND METHODS: From August 2024 to December 2025, an exploratory sequential mixed-methods study of clinicians who care for patients with PNs was performed. First, we conducted semi-structured qualitative interviews with 40 clinicians across multiple specialties prior to thematically analyzing interview transcripts to develop and administer a quantitative online survey nationwide. We descriptively analyzed survey data, triangulated results with representative interview quotes, and performed exploratory analyses assessing factors associated with survey responses selected by a priori study objectives and qualitative findings. RESULTS: Of 3,588 US clinicians invited via email to participate in the survey, 192 (5.4%) across general pulmonology, interventional pulmonology, thoracic surgery, and other specialties completed it. Most clinicians (70.8%) reported using risk assessment tools to evaluate PN cancer risk, with clinical risk prediction models (70.3%) more commonly used than commercial biomarkers (18.8%). Most participants (63.5%) believed that an ideal risk assessment tool should prioritize not missing a lung cancer diagnosis rather than avoiding unnecessary invasive procedures. Clinicians generally agreed that PN evaluation is challenging (71.4%) and requires shared decision-making (95.8%), multidisciplinary collaboration (91.1%), and improvement (85.9%). Only 50.5% reported having the clinical resources necessary to provide optimal PN care. Participants ranked PN tracking and risk assessment tools as the top priorities for improving PN clinical care. INTERPRETATION: Our results show that clinicians find PN evaluation challenging, requiring multidisciplinary collaboration, shared decision-making, and improvement, but many lack adequate resources to provide optimal care. Future efforts should focus on improving system-level PN tracking and cancer risk assessment.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Kim RY, Gupta A, Ang L, et al. Contemporary Pulmonary Nodule Evaluation and Management in the United States A Mixed-Methods Study. Chest. 2026. PMID: 42521153. doi:10.1016/j.chest.2026.06.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。